- Category
- Micro (2021-22)
- Udyam number
- UDYAM-MH-26-0225769

Specura Pharmaceuticals Private Limited
About Specura Pharmaceuticals Private Limited
Data last updated:
Specura Pharmaceuticals Private Limited is a private limited company based in Pune, Maharashtra, India. It operates in the chemical elements and compounds doped segment of the chemicals sector. It was incorporated on 30 December 2020 and has been in existence for over 6 years.
The company is registered with the Registrar of Companies (ROC), Pune, under CIN U24296PN2020PTC197339.
The company has an authorised share capital of ₹10,000 and a paid-up capital of ₹10,000. It is led by directors Yashwant Shivram Bhujbal and Rajendra Chandrashekhar Dixit.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Flat No. 18 Parvati Chambers S. No. 16/1 Opp. Karishma Soc. Kothrud, Pune, Maharashtra, India – 411038.
As per the financials filed for FY 2025, the company reported a revenue of ₹11.16 Lakh, a growth of 48% compared to the previous year. For the same year it recorded a net loss of ₹4.17 Lakh (net margin -37.4%) and EBITDA of ₹65,903 (EBITDA margin 5.9%). Revenue has grown at a compounded annual rate (CAGR) of 2% over three years.
Specura Pharmaceuticals Private Limited is registered as a micro enterprise under the Udyam registration framework (Reg. No. UDYAM-MH-26-0225769). The current compliance status is marked as compliant by the Registrar of Companies.
Company details
Recognitions & Rankings of Specura Pharmaceuticals
Contact details
Specura Pharmaceuticals Private Limited's registered office is in Pune, Maharashtra.
- Registered AddressFlat No. 18 Parvati Chambers S. No. 16/1 Opp. Karishma Soc. Kothrud, Pune, Maharashtra, India – 411038
- IndustryChemicals, Chemical Elements And Compounds Doped, Manufacturing, Other Chemical Product
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Specura Pharmaceuticals is trade. In detail, this covers wholesale trading.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading |
To see the full business activity and turnover split of Specura Pharmaceuticals Private Limited, buy the company report.
Financials of Specura Pharmaceuticals Private Limited
FY 2025 filings availableSpecura Pharmaceuticals Private Limited reported revenue of ₹11.16 Lakh (up 48% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 2% over three years, including 48% growth in the latest year. EBITDA rose 153% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹65,903 | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | -₹4.17 Lakh | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 5.9% | ||||
| Net Profit Margin | -37.4% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Specura Pharmaceuticals Private Limited, buy the company report.
Board of directors of Specura Pharmaceuticals Private Limited
Specura Pharmaceuticals has 2 directors on record. No former directors are listed.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Yashwant Shivram Bhujbal Also directs: Uniswen Pharmaceuticals Private Limited | Director | 30 Dec 2020 | 5 Years 10 Months | Current |
| Rajendra Chandrashekhar Dixit Also directs: Uniswen Pharmaceuticals Private Limited | Director | 30 Dec 2020 | 5 Years 10 Months | Current |
Peer comparison
Specura Pharmaceuticals Private Limited is compared with the 7 companies closest to it by revenue in the Pharma industry (Pharmaceuticals), with the same principal business activity (wholesale trading), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Brugen Pharmaceuticals Private Limited | ₹11.23 Lakh (FY 2025) | 88.0% | Jabalpur, Madhya Pradesh, India | |||
| Panmed Pharmaceuticals Private Limited | ₹11.21 Lakh (FY 2017) | -49.0% | Chennai, Tamil Nadu, India | |||
| Rynn Pharmaceuticals Private Limited | ₹11.21 Lakh (FY 2024) | -39.0% | Ghaziabad, Uttar Pradesh, India | |||
| Fronde Pharmaceuticals Private Limited | ₹11.2 Lakh (FY 2025) | -8.0% | Cuttack, Odisha, India | |||
| Altmann Pharmaceuticals Private Limited | ₹11.17 Lakh (FY 2025) | 30.0% | Karnal, Haryana, India | |||
| Specura Pharmaceuticals Private Limitedthis company | ₹11.16 Lakh (FY 2025) | -₹4.17 Lakh | -37.4% | 48.0% | Pune, Maharashtra, India | |
| Lifecord Pharmaceuticals Private Limited | ₹11.16 Lakh (FY 2019) | 132.0% | Ghaziabad, Uttar Pradesh, India | |||
| Lion in Pharmaceuticals India Private Limited | ₹11.13 Lakh (FY 2025) | -22.0% | Yelahanka, Karnataka, India |
To see the full peer comparison of Specura Pharmaceuticals Private Limited, buy the company report.
Legal cases
No court or tribunal cases involving Specura Pharmaceuticals Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Specura Pharmaceuticals Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
No GST registration is on our record for Specura Pharmaceuticals Private Limited; the GSTIN and return-filing check is in the company report Buy the company report.
Recent activity
Specura Pharmaceuticals Private Limited has 2 board changes on record since 2020: 2 appointments. The latest: Rajendra Chandrashekhar Dixit was appointed as Director on 30 Dec 2020.
Frequently asked questions
Specura Pharmaceuticals is an active private limited company based in Pune, Maharashtra, India. The company works in chemical elements and compounds doped, within the chemicals industry. It was incorporated on 30 December 2020 (6+ years old) and is registered under CIN U24296PN2020PTC197339.
Specura Pharmaceuticals has 2 current directors:
- Yashwant Shivram Bhujbal - Director
- Rajendra Chandrashekhar Dixit - Director
The latest financial statements of Specura Pharmaceuticals on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from FY 2021 are in the company report.
The CIN (Corporate Identification Number) of Specura Pharmaceuticals is U24296PN2020PTC197339. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Specura Pharmaceuticals was incorporated on 30 December 2020, making it 6+ years old. It is registered with the Registrar of Companies, Pune.
The peers of Specura Pharmaceuticals by revenue are Brugen Pharmaceuticals Private Limited, Panmed Pharmaceuticals Private Limited, Rynn Pharmaceuticals Private Limited, Fronde Pharmaceuticals Private Limited, Altmann Pharmaceuticals Private Limited and 2 more, all in the Pharma industry (Pharmaceuticals), with the same principal business activity (wholesale trading).
Rajendra Chandrashekhar Dixit was appointed as Director on 30 Dec 2020. Yashwant Shivram Bhujbal was appointed as Director on 30 Dec 2020.
Yes, Specura Pharmaceuticals is registered as a micro enterprise under Udyam registration (number: UDYAM-MH-26-0225769).
The registered office of Specura Pharmaceuticals is at Flat No. 18 Parvati Chambers S. No. 161 Opp. Karishma Soc. Kothrud, Pune, Maharashtra, India – 411038.
Specura Pharmaceuticals operates in the chemicals industry, in the chemical elements and compounds doped segment.
The compliance status of Specura Pharmaceuticals is compliant as of 12 July 2026. The company is actively filing with the Registrar of Companies.

